Alba Fiorentino, Full Professor of Radiation Oncology and Head of the Radiation Oncology Residency Program at LUM University of Medicine, Chief of Diagnostic and Therapeutic Department, Chief of Radiation Oncology at MIULLI.art H-index 32, shared a post on LinkedIn about an article she and her colleagues authored:
“Patients with Brain Metastases (BM) from HER2-positive BC exhibit distinct clinical characteristics when compared to other BC subtypes. These characteristics include a more frequent control of extracranial disease, a less common involvement of the leptomeninges, and a higher likelihood of lesions located in the posterior cranial fossa. Furthermore, they generally have a better prognosis from diagnosis, despite BM’s presence.
Therefore, in this context, the AIRO – Associazione Italiana di Radioterapia ed Oncologia Clinica Breast Cancer Study Group and the AIRO Neuro-oncological Study Group decided to jointly conduct the present systematic review to better define the RT strategy for patients with HER2-positive BC BMs.”
Title: Brain metastases for Her2 positive breast cancer patients: a systematic review (on the behalf of Italian Association of Radiotherapy and Clinical Oncology)
Authors: Alba Fiorentino, Roberta Carbonara, Edy Ippolito, Fiorella Cristina Di Guglielmo, Simona Borghesi, Francesca Cucciarelli, Carlotta Becherini, Samantha Dicuonzo, Ruggero Spoto, Valentina Pinzi, Silvia Chiesa, Silvia Scoccianti, Isabella Palumbo
More posts featuring Alba Fiorentino on OncoDaily.